CPRX
Price:
$21.62
Market Cap:
$2.58B
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; a...[Read more]
Industry
Biotechnology
IPO Date
2006-11-08
Stock Exchange
NASDAQ
Ticker
CPRX
According to Catalyst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.14B. This represents a change of 29.52% compared to the average of 1.65B of the last 4 quarters.
The mean historical Enterprise Value of Catalyst Pharmaceuticals, Inc. over the last ten years is 520.87M. The current 2.14B Enterprise Value has changed 40.98% with respect to the historical average. Over the past ten years (40 quarters), CPRX's Enterprise Value was at its highest in in the September 2024 quarter at 1.93B. The Enterprise Value was at its lowest in in the June 2016 quarter at 40.12M.
Average
520.87M
Median
246.76M
Minimum
73.13M
Maximum
1.65B
Discovering the peaks and valleys of Catalyst Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 280.15%
Maximum Annual Enterprise Value = 1.65B
Minimum Annual Increase = -56.95%
Minimum Annual Enterprise Value = 73.13M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.65B | 1.49% |
2022 | 1.63B | 205.88% |
2021 | 532.33M | 146.99% |
2020 | 215.52M | -27.48% |
2019 | 297.18M | 64.64% |
2018 | 180.50M | -35.07% |
2017 | 277.99M | 280.15% |
2016 | 73.13M | -56.95% |
2015 | 169.87M | -6.36% |
2014 | 181.41M | 109.92% |
The current Enterprise Value of Catalyst Pharmaceuticals, Inc. (CPRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.27B
5-year avg
865.16M
10-year avg
520.87M
Catalyst Pharmaceuticals, Inc.’s Enterprise Value is greater than Day One Biopharmaceuticals, Inc. (857.57M), greater than Terns Pharmaceuticals, Inc. (223.81M), greater than X4 Pharmaceuticals, Inc. (79.71M), greater than Inozyme Pharma, Inc. (210.44M), greater than Mereo BioPharma Group plc (510.15M), less than Exelixis, Inc. (9.59B), less than TG Therapeutics, Inc. (5.06B), less than Viking Therapeutics, Inc. (4.67B), less than Madrigal Pharmaceuticals, Inc. (6.69B), greater than BioXcel Therapeutics, Inc. (82.01M), less than Axsome Therapeutics, Inc. (4.08B), less than Incyte Corporation (12.20B), less than ImmunoGen, Inc. (8.19B), less than Sarepta Therapeutics, Inc. (12.84B), less than ACADIA Pharmaceuticals Inc. (2.73B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Hepion Pharmaceuticals, Inc. (4.21M), greater than Akero Therapeutics, Inc. (1.71B), less than Reata Pharmaceuticals, Inc. (6.64B),
Company | Enterprise Value | Market cap |
---|---|---|
857.57M | $1.28B | |
223.81M | $492.65M | |
79.71M | $98.92M | |
210.44M | $188.22M | |
510.15M | $589.54M | |
9.59B | $9.66B | |
5.06B | $5.01B | |
4.67B | $4.72B | |
6.69B | $6.80B | |
82.01M | $17.42M | |
4.08B | $4.22B | |
12.20B | $13.47B | |
8.19B | $8.73B | |
12.84B | $11.64B | |
2.73B | $2.84B | |
915.81M | $794.69M | |
4.21M | $3.48M | |
1.71B | $1.99B | |
6.64B | $6.57B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Catalyst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Catalyst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Catalyst Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Catalyst Pharmaceuticals, Inc. (CPRX)?
What is the 3-year average Enterprise Value for Catalyst Pharmaceuticals, Inc. (CPRX)?
What is the 5-year average Enterprise Value for Catalyst Pharmaceuticals, Inc. (CPRX)?
How does the current Enterprise Value for Catalyst Pharmaceuticals, Inc. (CPRX) compare to its historical average?